Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OLMETREAT: Olmesartan treat-to-target in hypertension
NCT00311155Phase 4Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Mar 2006
- Primary completion
- Apr 2008
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 4, open-label, single-arm trial of olmesartan in essential hypertension, sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Percentage of Participants Treated to Target Blood Pressure Goals Overall and for Each Treatment Step at 20 weeks. Started Mar 2006; status: completed.
02
Drugs
olmesartan
03
Conditions
essential hypertension
Beyond the preview
Go deeper on NCT00311155.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00311155.